<SEC-DOCUMENT>0001493152-26-034201.txt : 20260722
<SEC-HEADER>0001493152-26-034201.hdr.sgml : 20260722
<ACCEPTANCE-DATETIME>20260722120002
ACCESSION NUMBER:		0001493152-26-034201
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260722
FILED AS OF DATE:		20260722
DATE AS OF CHANGE:		20260722

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		261192754

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>July
2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B> 001-41386</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th
</SUP>Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2026, OKYO Pharma LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing that its Chairman, Mr. Gabriele Cerrone,
through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 22,500
ordinary shares at $1.45 per share, bringing his total holding to 10,873,916 ordinary shares, which is 20.55% of issued share capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company&rsquo;s Registration
Statement on Form F-3 (Reg. No. 333-293145)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO Pharma LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: July 22, 2026</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Keeren Shah</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">News Announcement, dated July 22, 2026</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="width: 237px; height: 53px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma Announces Purchase of Shares by Chairman</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London
and New York, NY, July 22, 2026. OKYO Pharma Limited (Nasdaq: <U>OKYO</U>), a clinical-stage biopharmaceutical company developing investigational
therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr.
Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the
purchase of 22,500 ordinary shares at $1.45 per share, bringing his total holding to 10,873,916 ordinary shares, which is 20.55% of issued
share capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OKYO Pharma</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic
corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans
to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate
a single-dose regimen of urcosimod for the treatment of NCP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further information, please visit <U>www.okyopharma.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
further inquiries:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma Ltd</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Spencer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
Development and Investor Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44
(0) 207 495 2379</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
info@okyopharma.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ^ 0\# 2(  A$! Q$!_\0
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MXJ-H5)WB^VS#"4\.[RA"TEWW0^FNBR(R.H=&&"K#((]#3J*\0]4_.O\ :_\
MV';K0+J^\:?#NQ:YTAR9K[1+=<R6IZL\*C[T?<J.5[9'W?F#X<?'7Q[\(Y\^
M%_$M]ID6<M:;_,MV/O$^4S[XS7[9U\Z_'']AWP#\8KBXU2UC?PKXAE)9[[3D
M'E3-ZRP\!C[J5)[DU]A@<[AR?5\<N:/>U_O77UW/FL7E4N?VV$?++MM]Q\R^
M%O\ @IUXUTZW6/7?"^D:TX_Y:V\DEHQ^OWQ^0%=7-_P5+_T8>5\._P#2.X?5
MOD_]$YKY_P#C?^R%XE^",C/?:SI6I6A3S$>W,JR%<XY4I@'_ ($:\<\-^'+G
MQ1JL6GVKQ1S2' :8D+^@-?0QRS+,1'VL8:?-?@>,\?CZ+]G*6OR9],?$'_@H
MW\2?%=M+:Z';Z=X3@D7:9;1#-<#Z2/P/J%!]Z^8[R]U3Q7K3W%S-=:OJMY+E
MI)6::::0GN3DL37V!\*/^";FK>*[*SU7Q)XMLK'39UWB'2XGFF89Z;G"A3[X
M:OLOX0_LQ_#WX)HDGA[1$?5 ,-JM\?.NF]<,1A/H@45QU,RR_+$X8:%Y>2M]
M[>OYG3# XW'M3KSM'^MDM/R/CGX*_L+>,_BO=6?B#XJZE?Z5I2H@BL)Y2]]-
M&!\J?-D0IC P>1TVCK7WWX&\ >'OAKX>@T3PSI5OI&FPCB&!<%CW9V/+,>[,
M2:Z"BOC,9F%?&O\ >.T5LELCZC#8.EA5[BU>[>["BBBO-.T^2?\ @J'_ ,FG
M:I_V%++_ -#->%_L_P"B?MB7'P7\(2>!M?\ #-MX1:P0Z9#=QVYE2')P&W0D
MYZ]2:^^/BS\(_#'QN\'2^%_%]B^H:-+-'.\$<[PDNARIW(0>OO6IX$\$:1\-
M_"&E>&- MVM-&TN 6]K"\C2%$'0%F))Z]2:].GBXT\.J2BF[WU5UL<$\,YUG
M4YK*UM'9GP;\1?@%^V3\<?#,OA'QCXJ\+)X=O)(VNA$T46X*P9<F*#<0" <#
MK@5]F?L^?"*#X$?!WPUX'@NOMYTJ!EFN@NT33.[22,!DX!=VP/3%>B45A5Q4
MZL%3LDM[)6U-J>'C3ESW;>VKN?CK^S%^RUIO[3_QA^*]GJ/B/4O#RZ1>M,CZ
M:%)E,EQ,"&W>FW]:^F/^'3'AC_HI?B?_ +XBKZD^%'[-_@+X)Z_X@UKPCI,N
MGZCKS![^22[EF$A#LXP'8A>7;ICK7IU=M?,JLJC=&34=.W8Y:.!IQA:HKOYG
MYD_\$Y?"$7P__;'^+?AF"ZEO8=(LKRQ2YGQYDHCO8D#-CN<9KZ6_;Y_:>'[/
MOPI?3]&N /&WB)7M--1#E[>/&)+C'^R#A?\ :(ZX->I^ _V<? ?PU^(_B+QU
MX?TJ6T\2^(/-_M"Z>[ED67S)!*^$9BJY< \ 51\:_LK?#CXB_$[3_'_B31IM
M6\1V#0M;/<7LQ@C\HY0"'=LP&^;&,$DDYS45,31K8E5JB;22^;7Z%0H5:5!T
MX-7N_N/@G]EC0_VB?V:]'U2;0/@0NM:AKC)//JNIW 6=H@,I'@2C:,EF((R2
M>>@QPGQ3N?C9\(OC=!^T#J/PP;X?D7D7VZ.TFW6EU(X*R"0!V*B5<@]MQS]X
MU^QE8?C?P5HOQ&\)ZIX:\0V*:EHNI0F"YMI"0'4^A&""" 01R" 16D<R_>.<
MZ:UT>^WWD2P/N*,9O3;;?[C/^%?Q+T7XP?#_ $7Q?X?G\_3-4@$R D;HFZ/&
M_HRL"I'J*_*+X4>$/BIXM_:;^."_"+Q,GASQ+9W.H7#H^U?ML7V_!A#LI"G)
M4@D8XP2.M?J3\&?@5X1^ >@7>B>#+2ZL-*N9_M+VL][+<*LFT*67S&.W( SC
MK@5G_#G]FOP!\*/'WB'QGX:TF:R\0:]YOV^X>\EE63S)1*^$9BJY< \ >E8T
M,33P_M.173VNO/J:5:$ZW)S.UM[?H?F;X=^//QWC^(-SX+^(_P :-4^%>K(0
MB/KFF*82Q)'S.B?*#V?[I_O"OMG]D?\ 8WM/@QXGU7XC:OXU;X@^+->@8'54
M7]QLD<.[JQ9C(SD+\^1QG YKVOXN? GP+\=-%33/&WAZVUF&([H9FS'/ ?\
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BG)QR3D\UJ\73J471G"RW5NC^;,_J\X5%5A*[V=^WR1__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
